文献速递临床试验与 GCP

我们的选择:中西医结合优化银屑病治疗实施随机对照试验研究方案

Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine.
PubMed 文献 · Trials · 2020-03-30

本研究为多中心、单盲、随机对照试验,纳入108例轻中度斑块状银屑病患者随机接受中药内服或外用治疗,270例重度患者随机接受中药、西药或中西药联合治疗,均治疗8周并随访8周,主要评价疗效与复发率。

要点

  • 轻中度斑块状银屑病患者随机接受中药内服或外用治疗,比较两种序贯策略。
  • 重度斑块状银屑病患者随机接受中药、西药或中西药联合治疗,评估联合方案。
  • 主要结局为基于PASI的疗效与复发率,次要结局包括BSA、PGA、瘙痒VAS等。

核心结论

  • 该试验旨在为中药内服与外用的优化选择及中西医结合治疗银屑病提供高级别临床证据。

研究设计与样本

  • 多中心、单盲、随机对照试验,轻中度患者108例按1:1随机分组,重度患者270例按1:1:1随机分组。
  • 所有入组患者接受8周治疗,治疗结束后8周进行随访评估。

关键数值与推荐

  • 主要结局为基于银屑病面积与严重程度指数(PASI)评估的疗效和复发率。
  • 次要结局包括受累体表面积、医师整体评估、瘙痒视觉模拟评分、中医症状评分、皮肤病生活质量指数、患者报告生活质量评分及严重不良事件发生率。

临床怎么用

  • 研究结果预期可为轻中度银屑病中药内服或外用的选择以及重度患者中西医结合方案的建立提供规范依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plaque psoriasis is a refractory inflammatory skin disease. The common therapies used to treat plaque psoriasis in traditional Chinese medicine (TCM) and western medicine (WM) have distinct characteristics and advantages. Although a combination of TCM and WM therapies, adjusted to the clinical situation, is widely used, there are no systematic studies on the hierarchical selection of this treatment combination based on the severity of skin lesions. We therefore designed a randomized clinical trial to focus on the sequence of internal and external treatments of TCM in patients with mild-to-moderate plaque psoriasis and to optimize the integration of Chinese and western medicine for the treatment of patients with severe plaque psoriasis, thereby achieving high-level clinical evidence and establish treatment norms for the integrated use of Chinese and western medicines. METHODS: In this proposed multicenter, single-blinded, randomized controlled trial, 108 patients with mild-to-moderate plaque psoriasis will be randomly assigned to two groups in a 1:1 ratio to receive either internal or external TCM treatment, and 270 patients with severe plaque psoriasis will be randomly assigned to three groups in a 1:1:1 ratio to receive treatment with TCM or WM, or TCM + WM. All enrolled patients will receive 8 weeks of treatment. Follow-up assessments will be done 8 weeks after the treatment. The primary outcome of this study is the evaluation of efficacy and relapse rate, based on the Psoriasis Area and Severity Index, and the secondary outcome measures include determination of the affected body surface area, physician's global assessment, pruritus scores (determined using a visual analog scale), TCM symptom score, Dermatology Life Quality Index, patient-reported quality of life score and incidence of serious adverse events. DISCUSSION: This study will provide high-level clinical evidence for internal and external TCM treatment optimization and will contribute to establishing norms for the integration of Chinese and western Medicines. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03941431. Registered on 8 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun X, Zhou X, Wei Y, et al. Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine. Trials. 2020. PMID: 32228720. doi:10.1186/s13063-020-4209-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。